Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease 

Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time 

In the NICHE-3 study, all patients achieved a pathological response  

Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens 

Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting 

Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed 

Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease

Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers

Encouraging preliminary results are reported with innovative antibody–drug conjugate designs, but underlying mechanisms of action still need to be described to improve efficacy and tolerability 

Disappointing results were reported from the phase III MANTRA trial, but biomarker-based approaches still offer hope for MDM2 inhibition in solid tumours